Novel therapeutic approach identified for overcoming resistance in B-cell leukemia

Despite having an overall survival rate of 94%, B-cell acute lymphoblastic leukemia (B-ALL), the most common childhood cancer, can prove challenging to treat, with survival among relapsed or resistant cases falling between 30-50%.

Related Keywords

Texas ,United States ,Xin Huang ,Zhejiang ,China ,Peking ,Beijing ,Xu Yang ,Shaanxi ,Charles Mullighan ,Seth Karol ,Steven Kornblau ,Junj Yang ,Xiaofan Zhu ,Sheetal Bhatara ,Yizhen Li ,Yingchi Zhang ,Satoshi Yoshimura ,Nitin Jain ,Jiyang Yu ,Marina Konopleva ,Jingliao Zhang ,Hiroto Inaba ,William Evans ,Wenjian Yang ,Elisabeth Paietta ,Elias Jabbour ,Mark Litzow ,Huanbin Zhao ,Leukemia Research ,Albert Einstein College Of Medicine ,Children Research Hospital ,Baldrick Foundation ,University Of Texas Md Anderson Cancer Center ,National Institutes Of Health ,Department Of Defense ,Drug Administration ,University Of Chicago ,Research Hospital ,Pharmaceutical Sciences ,Computational Biology ,Ching Hon Pui ,Fahad Nassar Al Rashid Endowed Chair ,Nature Cancer ,Chinese Academy ,Medical Sciences ,Peking Union Medical ,Peking Union Medical College ,Mayo Clinic ,Wendy Stock ,Cancer Center ,Albert Einstein College ,Lei Yan ,Liang Ding ,National Institutes ,Cell ,Dwell Development ,Leukemia ,Acute Lymphoblastic Leukemia ,Asparaginase ,B Cell ,Dancer ,Chemotherapy ,Children ,Drugs ,Gene ,Hospital ,Laboratory ,Pharmacy ,Protein ,Research ,Humor ,